Pfizer Isn’t Expecting to Make Any Big Acquisition in the Next Couple of Years, but It’s Planning to Do This Instead Acquisitions can be a double-edged sword for companies, as they can quickly bolster revenue and growth opportunities but also add costs and inefficiencies.
Healthcare giant Pfizer (NYSE: PFE) has been involved in numerous acquisitions in recent years as it has worked to strengthen its prospects; a major risk for the stock has been uncertainty about where its growth will come from, particularly as it faces patent cliffs on key drugs
One of the largest deals Pfizer made was the $43 billion acquisition of oncology company Seagen in 2023. It was a major acquisition that gave it some promising cancer-fighting medicines. But Pfizer isn’t expecting to make significant deals like this in the near future.
Here’s how it plans to adjust its strategy and what that could mean for investors. Pfizer looks to take a break from acquisitions When a company is aggressively pursuing acquisitions, it can make it difficult to avoid rising costs, as it may incur acquisition-related expenses and become bloated with additional workers and overhead. On Pfizer’s most recent earnings call, CEO Albert Bourla was asked if there would be any more significant acquisitions in the near future.